Mohammed Orloff
Concepts (238)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Predisposition to Disease | 12 | 2025 | 528 | 1.230 |
Why?
| | Hamartoma Syndrome, Multiple | 8 | 2012 | 15 | 1.020 |
Why?
| | Germ-Line Mutation | 9 | 2013 | 66 | 1.020 |
Why?
| | PTEN Phosphohydrolase | 13 | 2015 | 55 | 1.000 |
Why?
| | Barrett Esophagus | 2 | 2019 | 31 | 0.970 |
Why?
| | Esophageal Neoplasms | 2 | 2019 | 111 | 0.880 |
Why?
| | Adenocarcinoma | 3 | 2019 | 405 | 0.800 |
Why?
| | Haplotypes | 3 | 2020 | 94 | 0.740 |
Why?
| | Homozygote | 3 | 2019 | 58 | 0.640 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2021 | 506 | 0.630 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 170 | 0.600 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2012 | 172 | 0.560 |
Why?
| | Databases, Factual | 1 | 2020 | 706 | 0.530 |
Why?
| | Capacity Building | 2 | 2025 | 26 | 0.450 |
Why?
| | Alleles | 6 | 2021 | 277 | 0.440 |
Why?
| | Smoke-Free Policy | 2 | 2025 | 15 | 0.440 |
Why?
| | Lung Neoplasms | 3 | 2020 | 636 | 0.420 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2012 | 150 | 0.400 |
Why?
| | Genotype | 6 | 2021 | 569 | 0.390 |
Why?
| | Scavenger Receptors, Class A | 1 | 2011 | 39 | 0.360 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 69 | 0.360 |
Why?
| | Case-Control Studies | 5 | 2025 | 1201 | 0.300 |
Why?
| | Humans | 39 | 2025 | 52336 | 0.290 |
Why?
| | Genetic Variation | 3 | 2021 | 230 | 0.280 |
Why?
| | Transcription Factors | 1 | 2011 | 574 | 0.280 |
Why?
| | Breast Neoplasms | 7 | 2017 | 1206 | 0.280 |
Why?
| | Thyroid Neoplasms | 4 | 2012 | 116 | 0.270 |
Why?
| | Heart Defects, Congenital | 2 | 2024 | 618 | 0.260 |
Why?
| | Tobacco Smoke Pollution | 2 | 2025 | 55 | 0.250 |
Why?
| | Limb Deformities, Congenital | 1 | 2025 | 15 | 0.240 |
Why?
| | Genes, Wilms Tumor | 1 | 2005 | 1 | 0.240 |
Why?
| | Population | 1 | 2005 | 8 | 0.240 |
Why?
| | Gene Frequency | 3 | 2020 | 99 | 0.240 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2005 | 15 | 0.230 |
Why?
| | Social Justice | 1 | 2025 | 33 | 0.230 |
Why?
| | Genome | 2 | 2019 | 62 | 0.230 |
Why?
| | Female | 23 | 2025 | 28105 | 0.230 |
Why?
| | Evidence-Based Practice | 1 | 2025 | 111 | 0.230 |
Why?
| | Lamin Type A | 1 | 2024 | 6 | 0.220 |
Why?
| | Adult | 17 | 2025 | 14139 | 0.220 |
Why?
| | Middle Aged | 17 | 2025 | 13014 | 0.220 |
Why?
| | Exome | 2 | 2025 | 55 | 0.210 |
Why?
| | Linkage Disequilibrium | 2 | 2020 | 40 | 0.200 |
Why?
| | Male | 16 | 2025 | 26696 | 0.180 |
Why?
| | DNA Methylation | 2 | 2024 | 592 | 0.180 |
Why?
| | Inheritance Patterns | 1 | 2021 | 22 | 0.180 |
Why?
| | Phenotype | 7 | 2021 | 799 | 0.170 |
Why?
| | Models, Genetic | 5 | 2013 | 172 | 0.170 |
Why?
| | Risk Factors | 5 | 2019 | 3872 | 0.170 |
Why?
| | Succinate Dehydrogenase | 2 | 2011 | 22 | 0.170 |
Why?
| | Stilbenes | 2 | 2010 | 58 | 0.170 |
Why?
| | Fires | 1 | 2020 | 15 | 0.160 |
Why?
| | Agriculture | 1 | 2020 | 18 | 0.160 |
Why?
| | Aged | 11 | 2020 | 10109 | 0.160 |
Why?
| | Tobacco Products | 1 | 2021 | 127 | 0.160 |
Why?
| | Cluster Analysis | 4 | 2013 | 232 | 0.160 |
Why?
| | Social Media | 1 | 2021 | 117 | 0.160 |
Why?
| | Aged, 80 and over | 5 | 2020 | 3391 | 0.150 |
Why?
| | Arkansas | 5 | 2025 | 2028 | 0.150 |
Why?
| | Genomics | 1 | 2020 | 270 | 0.150 |
Why?
| | Cell Proliferation | 3 | 2010 | 1029 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 146 | 0.140 |
Why?
| | Prostatic Neoplasms | 2 | 2012 | 400 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2010 | 858 | 0.140 |
Why?
| | Young Adult | 8 | 2025 | 4319 | 0.140 |
Why?
| | Prognosis | 2 | 2020 | 2094 | 0.130 |
Why?
| | Endometrial Neoplasms | 2 | 2015 | 144 | 0.130 |
Why?
| | Leprosy | 1 | 2016 | 8 | 0.130 |
Why?
| | Hypertension | 1 | 2021 | 565 | 0.120 |
Why?
| | Emergency Service, Hospital | 1 | 2020 | 521 | 0.120 |
Why?
| | Asthma | 1 | 2020 | 316 | 0.120 |
Why?
| | Microsatellite Repeats | 2 | 2012 | 42 | 0.120 |
Why?
| | Regression Analysis | 2 | 2017 | 401 | 0.120 |
Why?
| | Smoking | 2 | 2025 | 518 | 0.120 |
Why?
| | Aromatase | 1 | 2015 | 8 | 0.120 |
Why?
| | Tuberculosis | 1 | 2016 | 152 | 0.120 |
Why?
| | Genetic Linkage | 2 | 2011 | 25 | 0.110 |
Why?
| | Sirolimus | 2 | 2010 | 67 | 0.100 |
Why?
| | Adolescent | 8 | 2021 | 6692 | 0.100 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2013 | 3 | 0.100 |
Why?
| | Genome-Wide Association Study | 2 | 2012 | 186 | 0.100 |
Why?
| | Smad4 Protein | 1 | 2013 | 6 | 0.100 |
Why?
| | Genetic Testing | 2 | 2010 | 130 | 0.100 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 17 | 0.100 |
Why?
| | Cohort Studies | 3 | 2012 | 1532 | 0.100 |
Why?
| | Colonic Polyps | 1 | 2013 | 39 | 0.100 |
Why?
| | Receptors, Cell Surface | 1 | 2013 | 113 | 0.100 |
Why?
| | Mitochondrial Diseases | 1 | 2012 | 45 | 0.100 |
Why?
| | Codon, Nonsense | 1 | 2012 | 28 | 0.090 |
Why?
| | Flavin-Adenine Dinucleotide | 1 | 2011 | 4 | 0.090 |
Why?
| | Antigens, CD | 1 | 2013 | 219 | 0.090 |
Why?
| | NAD | 1 | 2011 | 45 | 0.090 |
Why?
| | Genes, p53 | 1 | 2011 | 52 | 0.090 |
Why?
| | DNA, Neoplasm | 1 | 2012 | 146 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2012 | 108 | 0.090 |
Why?
| | Siblings | 1 | 2011 | 34 | 0.090 |
Why?
| | Taxoids | 1 | 2011 | 37 | 0.090 |
Why?
| | Adenoma | 1 | 2012 | 113 | 0.090 |
Why?
| | Risk | 1 | 2012 | 313 | 0.090 |
Why?
| | Gene Expression Profiling | 3 | 2012 | 1110 | 0.090 |
Why?
| | Software | 1 | 2013 | 279 | 0.090 |
Why?
| | Intestinal Polyps | 1 | 2010 | 7 | 0.090 |
Why?
| | Receptors, Androgen | 1 | 2010 | 47 | 0.080 |
Why?
| | Cephalometry | 1 | 2010 | 18 | 0.080 |
Why?
| | Colorectal Neoplasms | 2 | 2012 | 295 | 0.080 |
Why?
| | Tumor Microenvironment | 1 | 2012 | 255 | 0.080 |
Why?
| | Head | 1 | 2010 | 70 | 0.080 |
Why?
| | Gene Dosage | 1 | 2009 | 78 | 0.080 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2010 | 54 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 138 | 0.080 |
Why?
| | Patient Selection | 1 | 2010 | 259 | 0.080 |
Why?
| | Cell Communication | 1 | 2009 | 72 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2011 | 327 | 0.080 |
Why?
| | Age Factors | 1 | 2012 | 1127 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2011 | 985 | 0.070 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2010 | 165 | 0.070 |
Why?
| | United States | 3 | 2025 | 5182 | 0.070 |
Why?
| | Chromosome Mapping | 2 | 2021 | 155 | 0.070 |
Why?
| | Prevalence | 2 | 2021 | 1007 | 0.070 |
Why?
| | Prospective Studies | 4 | 2017 | 2428 | 0.070 |
Why?
| | Mass Screening | 1 | 2010 | 357 | 0.070 |
Why?
| | Rural Population | 2 | 2022 | 572 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2011 | 1436 | 0.060 |
Why?
| | Physical Chromosome Mapping | 1 | 2005 | 8 | 0.060 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 1222 | 0.060 |
Why?
| | Frasier Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
| | Denys-Drash Syndrome | 1 | 2005 | 2 | 0.060 |
Why?
| | DNA Copy Number Variations | 1 | 2025 | 117 | 0.060 |
Why?
| | Exons | 1 | 2005 | 102 | 0.060 |
Why?
| | Counseling | 1 | 2025 | 136 | 0.060 |
Why?
| | Child | 5 | 2020 | 7157 | 0.050 |
Why?
| | CpG Islands | 1 | 2024 | 121 | 0.050 |
Why?
| | Models, Theoretical | 1 | 2005 | 182 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 1006 | 0.050 |
Why?
| | Mutation | 2 | 2010 | 1351 | 0.050 |
Why?
| | Biopsy | 1 | 2005 | 604 | 0.050 |
Why?
| | Polyproteins | 1 | 2022 | 3 | 0.050 |
Why?
| | Smoking Cessation | 1 | 2025 | 315 | 0.050 |
Why?
| | Child, Preschool | 3 | 2020 | 4030 | 0.050 |
Why?
| | RNA, Viral | 1 | 2022 | 125 | 0.050 |
Why?
| | Risk Assessment | 2 | 2021 | 1323 | 0.050 |
Why?
| | Phosphoproteins | 1 | 2022 | 121 | 0.050 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2021 | 6 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 98 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 244 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2021 | 117 | 0.040 |
Why?
| | Loss of Heterozygosity | 2 | 2012 | 78 | 0.040 |
Why?
| | Stromal Cells | 2 | 2012 | 77 | 0.040 |
Why?
| | Nicotine | 1 | 2021 | 176 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2010 | 82 | 0.040 |
Why?
| | Self Report | 1 | 2021 | 208 | 0.040 |
Why?
| | Pedigree | 2 | 2010 | 126 | 0.040 |
Why?
| | Seasons | 1 | 2020 | 91 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 558 | 0.040 |
Why?
| | Air Pollution | 1 | 2020 | 49 | 0.040 |
Why?
| | Neoplasms | 1 | 2009 | 1305 | 0.040 |
Why?
| | Phosphorylation | 2 | 2010 | 531 | 0.040 |
Why?
| | Signal Transduction | 3 | 2010 | 1716 | 0.040 |
Why?
| | Gene Expression | 2 | 2012 | 623 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2012 | 879 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 943 | 0.040 |
Why?
| | Infant | 2 | 2020 | 3684 | 0.030 |
Why?
| | Angiopoietin-2 | 1 | 2017 | 14 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 1377 | 0.030 |
Why?
| | Angiopoietin-1 | 1 | 2017 | 16 | 0.030 |
Why?
| | Receptor, TIE-2 | 1 | 2017 | 16 | 0.030 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2017 | 35 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 47 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2017 | 87 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 186 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 158 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 1676 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2017 | 125 | 0.030 |
Why?
| | HapMap Project | 1 | 2015 | 3 | 0.030 |
Why?
| | Introns | 1 | 2015 | 54 | 0.030 |
Why?
| | Pilot Projects | 1 | 2016 | 719 | 0.030 |
Why?
| | Peutz-Jeghers Syndrome | 1 | 2013 | 2 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2013 | 83 | 0.020 |
Why?
| | Genome, Human | 1 | 2013 | 121 | 0.020 |
Why?
| | Validation Studies as Topic | 1 | 2012 | 10 | 0.020 |
Why?
| | Penetrance | 1 | 2012 | 7 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2012 | 126 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 124 | 0.020 |
Why?
| | Vincristine | 1 | 2011 | 88 | 0.020 |
Why?
| | Anthracyclines | 1 | 2011 | 32 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 74 | 0.020 |
Why?
| | Paclitaxel | 1 | 2011 | 90 | 0.020 |
Why?
| | Formazans | 1 | 2010 | 4 | 0.020 |
Why?
| | Tetrazolium Salts | 1 | 2010 | 15 | 0.020 |
Why?
| | Immunoblotting | 1 | 2010 | 119 | 0.020 |
Why?
| | Androgen Antagonists | 1 | 2010 | 11 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 83 | 0.020 |
Why?
| | Drug Synergism | 1 | 2010 | 148 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2011 | 232 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2010 | 155 | 0.020 |
Why?
| | Michigan | 1 | 2010 | 22 | 0.020 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2010 | 16 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2012 | 215 | 0.020 |
Why?
| | Point Mutation | 1 | 2010 | 70 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2010 | 87 | 0.020 |
Why?
| | Androgens | 1 | 2010 | 70 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2012 | 181 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 2011 | 208 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2010 | 79 | 0.020 |
Why?
| | Heredity | 1 | 2009 | 2 | 0.020 |
Why?
| | BRCA2 Protein | 1 | 2009 | 19 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2010 | 76 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2009 | 39 | 0.020 |
Why?
| | BRCA1 Protein | 1 | 2009 | 34 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 460 | 0.020 |
Why?
| | Mice, Nude | 1 | 2010 | 236 | 0.020 |
Why?
| | Proteins | 1 | 2012 | 354 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 288 | 0.020 |
Why?
| | Cell Cycle | 1 | 2010 | 240 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 276 | 0.020 |
Why?
| | Protein Binding | 1 | 2011 | 680 | 0.020 |
Why?
| | Algorithms | 1 | 2013 | 668 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1044 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 602 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2009 | 93 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 278 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 474 | 0.020 |
Why?
| | Incidence | 1 | 2012 | 1059 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2009 | 184 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2010 | 340 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2008 | 84 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2011 | 770 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 412 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2011 | 674 | 0.020 |
Why?
| | Chromosome Aberrations | 1 | 2009 | 297 | 0.020 |
Why?
| | Survival Rate | 1 | 2010 | 940 | 0.020 |
Why?
| | Registries | 1 | 2010 | 580 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 5407 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2005 | 41 | 0.020 |
Why?
| | Time Factors | 1 | 2010 | 2957 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2005 | 1214 | 0.010 |
Why?
| | Mice | 1 | 2010 | 5965 | 0.010 |
Why?
| | Animals | 1 | 2010 | 13523 | 0.010 |
Why?
|
|
Orloff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|